Modification of Daxx by small ubiquitin-related modifier-1

Biochemical and Biophysical Research Communications

Volumn 295, Issue 2, 2002, Pages 495-500

  Jang, Moon Sun ^a   Ryu, Seung Wook ^a   Kim, Eunhee ^a  

^a PaiChai University   (South Korea)

Author keywords

Daxx; Modification; POD; SUMO 1; Sumoylation

Indexed keywords

DAXX PROTEIN; PROTEIN; SUMO 1 PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL STRAIN; CONTROLLED STUDY; EMBRYO; HUMAN; HUMAN CELL; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; SUMOYLATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CARRIER PROTEINS; CELL LINE; CELL NUCLEUS; CONSENSUS SEQUENCE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NUCLEAR PROTEINS; PROTEIN TRANSPORT; SUMO-1 PROTEIN;

EID: 0036066181     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-291X(02)00699-X     Document Type: Article

References (43)

1. Daxx, a novel Fas-binding protein that activates JNK and apoptosis
2. Activation of apoptosis signal-regulating kinase 1 (ASK1) by the adapter protein Daxx
3. Loss of Daxx, a promiscuously interacting protein, results in extensive apoptosis in early mouse development
4. Human Daxx regulates Fas-induced apoptosis from nuclear PML oncogenic domains (PODs)
5. Interphase-specific association of intrinsic centromere protein CENP-C with HDaxx, a death domain-binding protein implicated in Fas-mediated cell death
6. Cloning and expression of primate Daxx cDNAs and mapping of the human gene to chromosome 6p21.3 in the MHC region
7. The Pax3-FKHR oncoprotein is unresponsive to the Pax3-associated repressor hDaxx
8. PML is critical for ND10 formation and recruits the PML-interacting protein daxx to this nuclear structure when modified by SUMO-1
9. Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia
10. Review: Properties and assembly mechanisms of ND10, PML bodies, or PODs
11. Sequestration and inhibition of Daxx-mediated transcriptional repression by PML
12. The t(15;17) translocation alters a nuclear body in a retinoic acid-reversible fashion
13. Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus
14. Evidence for covalent modification of the nuclear dot-associated proteins PML and Sp100 by PIC1/SUMO-1
15. Localization of nascent RNA and CREB binding protein with the PML-containing nuclear body
16. Functional analysis and intracellular localization of p53 modified by SUMO-1
17. A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein
18. Role of SUMO-1-modified PML in nuclear body formation
19. Promyelocytic leukemia protein (PML) and Daxx participate in a novel nuclear pathway for apoptosis
20. Protection against Fas/APO-1- and tumor necrosis factor-mediated cell death by a novel protein, sentrin
21. A novel ubiquitin-like modification modulates the partitioning of the Ran-GTPase-activating protein RanGAP1 between the cytosol and the nuclear pore complex
22. Associations of UBE2I with RAD52, UBL1, p53, and RAD51 proteins in a yeast two-hybrid system
23. PIC 1 a novel ubiquitin-like protein which interacts with the PML component of a multiprotein complex that is disrupted in acute promyelocytic leukaemia
24. Versatile protein tag, SUMO: Its enzymology and biological function
25. Structure determination of the small ubiquitin-related modifier SUMO-1
26. The ubiquitin-like protein Smt3p is activated for conjugation to other proteins by an Aos1p/Uba2p heterodimer
27. An E3-like factor that promotes SUMO conjugation to the yeast septins
28. Involvement of PLAS1 in the sumoylation of tumor suppressor p53
29. Yeast Ull1/Siz1 is a novel SUMO-1/Smt3-ligase for septin components and functions as an adaptor between conjugating enzyme and substrates
30. SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting
31. Preferential interaction of sentrin with a ubiquitin-conjugating enzyme
32. SUMO-1 modification of IκBα inhibits NF-κB activation
33. SUMO-1 modification activates the transcriptional response of p53
34. The nuclear dot protein sp100, characterization of domains necessary for dimerization, subcellular localization, and modification by small ubiquitin-like modifiers
35. Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1
36. Covalent modification of the homeodomain-interacting protein kinase 2 (HIPK2) by the ubiquitin-like protein SUMO-1
37. Molecular characterization of the SUMO-1 modification of RanGAP1 and its role in nuclear envelope association
38. Ubc9p and the conjugation of SUMO-1 to RanGAP1 and RanBP2
39. Cell cycle-regulated attachment of the ubiquitin-related protein SUMO to the yeast septins
40. Interaction of Daxx, a Fas binding protein, with sentrin and Ubc9
41. The small ubiquitin-like modifier-1 (SUMO-1) consensus sequence mediates Ubc9 binding and is essential for SUMO-1 modification
42. Regulation of p53 activity in nuclear bodies by a specific PML isoform
43. P53 and PML: New partners in tumor suppression